~~<i id='C7EB2214BC'><strike id='C7EB2214BC'><tt id='C7EB2214BC'><pre id='C7EB2214BC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

fashion

author：leisure time 2025-09-29 22:46:51 - browse：2741

Biotech and life sciences investors continue to draw in new funds even as the biotech stock indexes reach new lows.

On Wednesday, VC firm Bioluminescence Ventures launched with $477 million to invest in biotech startups. The firm was founded by Kouki Harasaki, who was previously a partner at M12, Microsoft’s corporate venture group, and Andreessen Horowitz. He also has a track record at pharmaceutical companies like Novartis and Baxalta.

Bioluminescence joined at least four other firms — OrbiMed, Sofinnova Partners, Abingworth, and Revelation Partners — in announcing new pools of capital in the last two weeks. Together, they have raised $5.94 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Biotech lab space demand falls sharply

Wikipedia

explore

knowledge

hotspot

knowledge

hotspot

AdobeIntoday’smostlyplague-andfamine-freeworld,ifyoucanavoidmoremodernscourgeslikegunandcarviolence,

WSS

Mayo Clinic plans $5B tech

It's been 20 years since Dolly the sheep. Where's my clone?

Cigna, Humana reportedly in talks to merge

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Mayo Clinic plans $5B tech

What Congress can do to address the rural doctor shortage

leisure time

fashion

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

It's been 20 years since Dolly the sheep. Where's my clone?

Medicare proposal to cover medical devices draws a mixed reaction

Pediatric cancer treatments threatened by a new FDA policy

BioMarin wins approval for gene therapy to treat hemophilia A

U.K. Biobank has 500,000 peoples' genome sequences available

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Continuity nursing helped my family in our darkest PICU moments

The EPA's new lead rule: How one expert crunched the numbers

explore

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

UnitedHealth’s Optum accused of antitrust violations in California

Senators: Long

FDA panel to weigh approval of NurOwn, controversial ALS drug

Microbiome research is starting to find links to chronic diseases

Drug for rare kidney disease narrowly misses mark in clinical trial

knowledge

hotspot

knowledge

hotspot